LOPRESSOR (metoprolol tartrate) · XTM CONSULTING
1 IND ICATIONS AND USAGE LOPRESSOR is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Angina Pectoris. Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamicall...
Development Insights
Details
- Status
- Prescription
- First Approved
- 1978-08-07
- Routes
- ORAL, INJECTION
- Dosage Forms
- TABLET, INJECTABLE, TABLET, EXTENDED RELEASE, SOLUTION
LOPRESSOR Approval History
What LOPRESSOR Treats
3 indicationsLOPRESSOR is approved for 3 conditions since its original approval in 1978. These indications span multiple therapeutic areas including oncology, immunology, and more.
LOPRESSOR Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in LOPRESSOR's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications LOPRESSOR treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to LOPRESSOR
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
5 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT03138603 ORION results posted | IRB19-1797 5R01HL126892 | Ph 3 | completed | Metoprolol to Reduce Perioperative Myocardial Injury |
| NCT07268170 HEART-BEAT | 2025-522741-21-00 2025-522741-21-00 | Ph 2, Ph 3 | enrolling by invitation | Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease |
| NCT06864234 BEACON | 2025/032 | Ph 4 | recruiting | Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA |
| NCT05008250 | 2013019 | Ph 4 | completed | Efficacy and Safety of Metoprolol Tartrate Tablets Combined With Chinese Traditional Medicine on Premature Ventricular Complex. |
| NCT03457597 | CORT125134-126 | Ph 1 | completed | Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
LOPRESSOR FDA Label Details
Indications & Usage
FDA Label (PDF)1 IND ICATIONS AND USAGE LOPRESSOR is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Angina Pectoris. Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. 1.1 Hypertension LOPRESSOR is indicated for the treatment of hypertension in adul...
Track LOPRESSOR with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment